

Abacavir

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
Oral > Solid: 300 mg tablet (as sulfate)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Abacavir + lamivudine

Section

Fixed-dose combinations of antiretrovirals
Oral > Solid: 120 mg (as sulfate) + 60 mg tablet (dispersible, scored)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Abacavir + lamivudine + lopinavir + ritonavir

Section

Fixed-dose combinations of antiretrovirals
Oral > Solid: 30 mg + 15 mg + 40 mg + 10 mg capsule containing oral granules

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Atazanavir

Section

Antiretrovirals > Protease inhibitors
Oral > Solid: 100 mg (as sulfate); 300 mg (as sulfate)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Atazanavir + ritonavir

Section

Antiretrovirals > Protease inhibitors
Oral > Solid: 300 mg (as sulfate) + 100 mg tablet (heat stable)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Cobicistat + elvitegravir + emtricitabine + tenofovir disoproxil fumarate

Section

Fixed-dose combinations of antiretrovirals
Oral > Solid: 150 mg + 150 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Cobicistat + elvitegravir + emtricitabine+ tenofovir alafenamide

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 150 mg + 150 mg + 200 mg + 10 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Darunavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 75 mg; 400 mg; 600 mg; 800 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Didanosine

Section	Indications
Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors Oral > Liquid: 100 mg buffered powder for oral solution; 167 mg buffered powder for oral solution; 250 mg buffered powder for oral solution Oral > Solid: 25 mg buffered chewable dispersible tablet; 50 mg buffered chewable dispersible tablet; 100 mg buffered chewable dispersible tablet; 150 mg buffered chewable dispersible tablet; 200 mg buffered chewable dispersible tablet; 125 mg unbuffered enteric coated capsule; 200 mg unbuffered enteric coated capsule; 250 mg unbuffered enteric coated capsule; 400 mg unbuffered enteric coated capsule	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Dolutegravir

Section	Indications
Antiretrovirals > Integrase inhibitors Oral > Solid: 50 mg tablet; 10 mg tablet (dispersible, scored)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Dolutegravir + lamivudine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 50 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Efavirenz

Section

Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors
Oral > Solid: 600 mg tablet

Indications

Human immunodeficiency virus disease
without mention of associated disease or
condition, clinical stage unspecified

Efavirenz + emtricitabine + tenofovir

Section

Fixed-dose combinations of antiretrovirals
Oral > Solid: 600 mg + 200 mg + 300 mg (tenofovir disoproxil fumarate
equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease
without mention of associated disease or
condition, clinical stage unspecified

Efavirenz + lamivudine + tenofovir

Section

Fixed-dose combinations of antiretrovirals
Oral > Solid: 400 mg + 300 mg + 300 mg (tenofovir disoproxil fumarate,
equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease
without mention of associated disease or
condition, clinical stage unspecified

Therapeutic equivalent to efavirenz + emtricitabine +
tenofovir for

Human immunodeficiency virus disease
without mention of associated disease or
condition, clinical stage unspecified

Emtricitabine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors
Oral > Liquid: 10 mg per mL
Oral > Solid: 200 mg

Indications

Human immunodeficiency virus disease
without mention of associated disease or
condition, clinical stage unspecified

Emtricitabine + rilpivirine + tenofovir alafenamide

Section

Fixed-dose combinations of antiretrovirals
Oral > Solid: 200 mg + 25 mg + 25 mg

Indications

Human immunodeficiency virus disease
without mention of associated disease or
condition, clinical stage unspecified

Emtricitabine + rilpivirine + tenofovir disoproxil fumarate

Section

Fixed-dose combinations of antiretrovirals
Oral > Solid: 200 mg + 25 mg + 300 mg (tenofovir disoproxil fumarate
equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease
without mention of associated disease or
condition, clinical stage unspecified

Emtricitabine + tenofovir

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 200 mg + 300 mg (tenofovir disoproxil fumarate equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Contact with or exposure to human immunodeficiency virus

Emtricitabine + tenofovir alafenamide

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 200 mg + 10 mg; 200 mg + 25 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Indinavir

Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 400 mg (as sulfate)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Isoniazid + pyridoxine + sulfamethoxazole + trimethoprim

Section

Medicines for prevention of HIV-related opportunistic infections

Oral > Solid: 300 mg + 25 mg + 800 mg + 160 mg tablet (scored)

Indications

Other specified prophylactic measures

Lamivudine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Liquid: 50 mg per 5 mL

Oral > Solid: 150 mg tablet

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Lamivudine + nevirapine + zidovudine

Section

Fixed-dose combinations of antiretrovirals

Oral > Solid: 30 mg + 50 mg + 60 mg Tablet; 150 mg + 200 mg + 300 mg

Tablet

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Lamivudine + tenofovir

Section	Indications
Fixed-dose combinations of antiretrovirals	Therapeutic equivalent to emtricitabine + tenofovir for Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified Therapeutic equivalent to emtricitabine + tenofovir for Contact with or exposure to human immunodeficiency virus

Lamivudine + zidovudine

Section	Indications
Fixed-dose combinations of antiretrovirals Oral > Solid: 30 mg + 60 mg Tablet; 150 mg + 300 mg Tablet	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Lopinavir + ritonavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 100 mg + 25 mg tablet (heat-stable); 200 mg + 50 mg tablet (heat-stable); 40 mg + 10 mg	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Nelfinavir

Section	Indications
Antiretrovirals > Protease inhibitors Oral > Solid: 250 mg (as mesilate) Oral > Other: 50 mg per g oral powder	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Nevirapine

Section	Indications
Antiretrovirals > Non-nucleoside reverse transcriptase inhibitors Oral > Liquid: 50 mg per 5 mL oral solution Oral > Solid: 200 mg tablet; 50 mg tablet (dispersible)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Raltegravir

Section	Indications
Antiretrovirals > Integrase inhibitors Oral > Liquid: 100 mg granules for oral suspension Oral > Solid: 400 mg tablet; 25 mg tablet (chewable)	Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Ritonavir

Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 25 mg tablet (heat stable); 100 mg tablet (heat stable)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Saquinavir

Section

Antiretrovirals > Protease inhibitors

Oral > Solid: 200 mg; 500 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Stavudine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Liquid: 5 mg per 5 mL powder for oral solution

Oral > Solid: 15 mg; 20 mg; 30 mg

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Tenofovir disoproxil fumarate

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Oral > Solid: 300 mg tablet (equivalent to 245 mg tenofovir disoproxil)

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified

Contact with or exposure to human immunodeficiency virus

Zidovudine

Section

Antiretrovirals > Nucleoside/Nucleotide reverse transcriptase inhibitors

Parenteral > General injections > IV: 10 mg per mL in 20 mL vial solution for IV infusion injection

Oral > Liquid: 50 mg per 5 mL

Oral > Solid: 250 mg capsule; 300 mg tablet

Indications

Human immunodeficiency virus disease without mention of associated disease or condition, clinical stage unspecified